Jens U Marquardt
Overview
Explore the profile of Jens U Marquardt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
139
Citations
2731
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gairing S, Mildenberger P, Gile J, Artusa F, Scheiner B, Leyh C, et al.
JHEP Rep
. 2025 Mar;
7(3):101295.
PMID: 40059970
Background & Aims: Immunotherapy with atezolizumab and bevacizumab (a + b) has improved the prognosis of patients with unresectable hepatocellular carcinoma (HCC). However, the outcome for individual patients is highly...
2.
Engelke C, Hatem Y, Maass C, Kraus M, Thomaschewski M, Jacob F, et al.
Endosc Int Open
. 2025 Feb;
13:a24200499.
PMID: 39958666
Background And Study Aims: Endoscopic vacuum-assisted closure (EVAC) of postsurgical leaks is an increasingly applied technique. Precise intracavitary sponge placement is technically challenging. Here, we describe a novel EVAC therapy...
3.
Cappuyns S, Pique-Gili M, Esteban-Fabro R, Philips G, Balaseviciute U, Pinyol R, et al.
J Hepatol
. 2024 Dec;
PMID: 39709141
Background & Aims: The combination of atezolizumab and bevacizumab (atezo+bev) is the current standard of care for advanced hepatocellular carcinoma (HCC), providing a median overall survival (OS) of 19.2 months....
4.
de Castro T, Welland S, Jochheim L, Leyh C, Shmanko K, Finkelmeier F, et al.
Hepatol Commun
. 2024 Nov;
8(11).
PMID: 39495153
Background: Immunotherapy-based combinations are currently the standard of care in the systemic treatment of patients with HCC. Recent studies have reported unexpectedly long survival with lenvatinib (LEN), supporting its use...
5.
Schlemmer C, Voigtlander T, Drews J, Engelke C, Marquardt J, Heidrich B, et al.
Surg Endosc
. 2024 Sep;
38(12):7158-7164.
PMID: 39347958
Background: Segmented self-expanding metal stents (SEMS) are an alternative to conventional unsegmented SEMS in the treatment of esophageal strictures. Due to their segmented design, they may adapt better to the...
6.
Asaad S, Chillon T, Filipowicz D, Wilms B, Strenge F, Szczepanek-Parulska E, et al.
Biofactors
. 2024 Sep;
51(1):e2123.
PMID: 39345206
The thyroid hormone (TH) status is routinely assessed by thyrotropin (TSH) and thyroxine (T4). Both biomarkers are mainly regulated by TH receptor beta, whereas many peripheral organs employ the alpha...
7.
Mitzlaff K, Kirstein M, Muller C, Venerito M, Olkus A, Dill M, et al.
United European Gastroenterol J
. 2024 Sep;
12(9):1230-1242.
PMID: 39301763
Background: Combined Immuno-chemotherapy consisting of gemcitabine, cisplatin and the programmed death-ligand one inhibitor durvalumab (GCD) is the new standard of care for patients with biliary tract cancers (BTC) based on...
8.
Wiegand J, Franke A, Muller T, Stein K, Bantel H, Gunther R, et al.
Z Gastroenterol
. 2024 Sep;
62(11):1931-1942.
PMID: 39227008
Real-world data on the management of patients with primary biliary cholangitis (PBC) are so far scarce in Germany. Therefore, we aimed to establish a nationwide registry and describe the clinical...
9.
Fererberger T, Buechler C, Kandulski A, Elger T, Loibl J, Schmid S, et al.
Front Med (Lausanne)
. 2024 Jun;
11:1334865.
PMID: 38895187
Intoduction: Identification of specific metabolome and lipidome profile of patients with primary sclerosing cholangitis (PSC) is crucial for diagnosis, targeted personalized therapy, and more accurate risk stratification. Methods: Nuclear magnetic...
10.
Schmithals C, Kakoschky B, Denk D, von Harten M, Klug J, Hintermann E, et al.
EBioMedicine
. 2024 Jun;
105:105178.
PMID: 38889481
Background: The accuracy of blood-based early tumour recognition is compromised by signal production at non-tumoral sites, low amount of signal produced by small tumours, and variable tumour production. Here we...